Search Results | Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Abstract 3526: Beta-oxidation inhibition as a novel therapy for cisplatin-resistant ovarian cancer

Miran Rada, Jennifer Cha, Jessica Sage, Bo Zhou, Wei Yang, Zahra Ashkavand, Kenneth Norman, Sandra Orsulic, Dong-Joo Cheon

Cancer Res (2018) 78 (13_Supplement): 3526.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3526

Published: 01 July 2018

View article

Journal Articles

Abstract 1009: Reciprocal roles of cancer associated fibroblasts and CD4+ T cells in ovarian cancer progression

Ye Hu, Sandra Orsulic

Cancer Res (2018) 78 (13_Supplement): 1009.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1009

Published: 01 July 2018

View article

Journal Articles

Abstract 5435: Role of the WT1 transcription factor in high-grade serous ovarian cancer

Norma I. Rodriguez-Malave, Justyna E. Kanska, Kevin C. Vavra, Dennis Hazelett, Rosario I. Corona, Ji-Heui Seo, Matthew Freedman, Simon R. Knott, Sandra Orsulic, Beth Y. Karlan, Kate Lawrenson, Simon A. Gayther

Cancer Res (2018) 78 (13_Supplement): 5435.

DOI: https://doi.org/10.1158/1538-7445.AM2018-5435

Published: 01 July 2018

View article

Journal Articles

Abstract 3650: Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

Liliane Robillard, Minh Nguyen, Andrea Loehr, Sandra Orsulic, Rebecca S. Kristeleit, Kevin Lin, Mitch Raponi, Thomas C. Harding, Andrew D. Simmons

Cancer Res (2017) 77 (13_Supplement): 3650.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3650

Published: 01 July 2017

View article

Journal Articles

Abstract 2975: Collagen type XI alpha 1 confers cisplatin chemoresistance in ovarian cancer through inhibitor of apoptosis proteins (IAPs)

Miran Rada, Jennifer Cha, Jessica Sage, Sandra Orsulic, Dong-Joo Cheon

Cancer Res (2017) 77 (13_Supplement): 2975.

DOI: https://doi.org/10.1158/1538-7445.AM2017-2975

Published: 01 July 2017

View article

Journal Articles

Abstract A39: COL11A1 is a regulator of tumor microenvironment and a biomarker of metastatic progression

Dong-Joo Cheon, Jessica Beach, Ann Walts, Beth Karlan, Sandra Orsulic

Cancer Res (2015) 75 (1_Supplement): A39.

DOI: https://doi.org/10.1158/1538-7445.CHTME14-A39

Published: 12 January 2015

View article

Journal Articles

Abstract B09: Sphingosine kinase 1 (SPHK1) is a novel mediator of tumor-stroma interaction in ovarian cancer

Jessica A. Beach, Paul-Joseph Aspuria, Dong-Joo Cheon, Maricel C. Gozo, Beth Y. Karlan, Sandra Orsulic

Cancer Res (2015) 75 (1_Supplement): B09.

DOI: https://doi.org/10.1158/1538-7445.CHTME14-B09

Published: 12 January 2015

View article

Journal Articles

Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance

Barbie Taylor-Harding, Hasmik Agadjanian, Paul-Joseph Aspuria, Dong-Joo Cheon, Takako Mizuno, Danielle Greenberg, Jenieke R. Allen, Sandra Orsulic, Christine Walsh, Beth Y. Karlan, W. Ruprecht Wiedemeyer

Cancer Res (2014) 74 (19_Supplement): 678.

DOI: https://doi.org/10.1158/1538-7445.AM2014-678

Published: 01 October 2014

View article

Journal Articles

Abstract 1534: Identification of LMX1B as a novel oncogene in human ovarian cancer

Gayatry Mohapatra, Lei He, Lankai Guo, Vinod Vathipadiekal, Petra Sergent, Whitfield Growdon, Bo Rueda, David Engler, Sandra Orsulic, Michael Birrer

Cancer Res (2014) 74 (19_Supplement): 1534.

DOI: https://doi.org/10.1158/1538-7445.AM2014-1534

Published: 01 October 2014

View article

Journal Articles

Abstract 1511: Stromal gene signature regulated by TGFβ signaling predicts poor clinical outcome in ovarian cancer .

Dong-Joo Cheon, Yunguang Tong, Myung-Shin Sim, Xiaojiang Cui, Dror Berel, Mourad Tighiouart, Wolf Ruprecht Wiedemeyer, Beth Karlan, Sandra Orsulic

Cancer Res (2013) 73 (8_Supplement): 1511.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1511

Published: 15 April 2013

View article

Journal Articles

Abstract 5443: FOXC1 is a critical mediator of EGFR function in basal-like breast cancer.

Yanli Jin, Bingchen Han, Wolf Ruprecht Wiedemeyer, Sandra Orsulic, Beth Karlan, Armando Giuliano, Xiaojiang Cui

Cancer Res (2013) 73 (8_Supplement): 5443.

DOI: https://doi.org/10.1158/1538-7445.AM2013-5443

Published: 15 April 2013

View article

Journal Articles

Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers.

Hasmik Agadjanian, Dong-Joo Cheon, Elena Diaz, Anna Laury, Carl Miller, Beth Karlan, Sandra Orsulic, Christine Walsh

Cancer Res (2013) 73 (8_Supplement): 329.

DOI: https://doi.org/10.1158/1538-7445.AM2013-329

Published: 15 April 2013

View article

Journal Articles

Abstract 1749: Cell cycle requirements shape ovarian cancer progression.

Barbie Taylor-Harding, Hasmik Agadjanian, Sandra Orsulic, Christine Walsh, Beth Y. Karlan, Wolf-Ruprecht Wiedemeyer

Cancer Res (2013) 73 (8_Supplement): 1749.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1749

Published: 15 April 2013

View article

Journal Articles

Abstract 1088: HOXB13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines.

Paul-Joseph Aspuria, Dong-Joo Cheon, Maricel Gozo, Brenda Salumbides, Laurent Vergnes, John Asara, Karen Reue, Elizabeth Kensicki, Beth Karlan, Sandra Orsulic

Cancer Res (2013) 73 (8_Supplement): 1088.

DOI: https://doi.org/10.1158/1538-7445.AM2013-1088

Published: 15 April 2013

View article

Journal Articles

Abstract 1578: MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer

Jianping Yuan, Pierre Leblanc, Satoshi Kashiwagi, Jean Nezivar, Elda Righi, Michael Santosuosso, Svetlana Korochkina, Sandra Orsulic, Nathalie Scholler, Glenn Dranoff, Jeffrey Gelfand, Mark Poznansky

Cancer Res (2012) 72 (8_Supplement): 1578.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1578

Published: 15 April 2012

View article

Journal Articles

Abstract 5093: Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome

David Engler, Sumeet Gupta, Whitfield Growdan, Ronny Drapkin, Mai Nitta, Petra Sergent, Serena Allred, Jenny Gross, Michael Deavers, Wen-Lin Kuo, Beth Karlan, Bo Rueda, Sandra Orsulic, David Gershenson, Michael Birrer, Joe Gray, Gayatry Mohapatra

Cancer Res (2012) 72 (8_Supplement): 5093.

DOI: https://doi.org/10.1158/1538-7445.AM2012-5093

Published: 15 April 2012

View article

Journal Articles

Abstract 3474: Ovarian cancer tumor initiating cells persist after paclitaxel and carboplatinum treatment in vivo

Kashmira S. Kulkarni-Datar, Sandra Orsulic, Rosemary Foster, Bo R. Rueda

Cancer Res (2012) 72 (8_Supplement): 3474.

DOI: https://doi.org/10.1158/1538-7445.AM2012-3474

Published: 15 April 2012

View article

Journal Articles

CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer

Elda Righi, Satoshi Kashiwagi, Jianping Yuan, Michael Santosuosso, Pierre Leblanc, Rachel Ingraham, Benjamin Forbes, Beth Edelblute, Brian Collette, Deyin Xing, Magdalena Kowalski, Maria Cristina Mingari, Fabrizio Vianello, Michael Birrer, Sandra Orsulic, Glenn Dranoff, Mark C. Poznansky

Cancer Res (2011) 71 (16): 5522–5534.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-3143

Published: 11 August 2011

View article

Includes: Supplementary data

Journal Articles

Abstract LB-387: Blockade of the CXCL12/CXCR4 axis with AMD3100 induces multimodal antitumor effects in murine ovarian cancer and prolongs survival

Satoshi Kashiwagi, Elda Righi, Jianping Yuan, Michael Santosuosso, Rachel Ingraham, Sandra Orsulic, Michael Birrer, Richard Penson, Glenn Dranoff, Mark C. Poznansky

Cancer Res (2011) 71 (8_Supplement): LB-387.

DOI: https://doi.org/10.1158/1538-7445.AM2011-LB-387

Published: 15 April 2011

View article

Journal Articles

Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene

Chad A. Hall, Runsheng Wang, Jiangyong Miao, Esther Oliva, Xiaoyun Shen, Thomas Wheeler, Susan G. Hilsenbeck, Sandra Orsulic, Scott Goode

Cancer Res (2010) 70 (21): 8517–8525.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-1242

Published: 31 October 2010

View article

Includes: Supplementary data

NARROW

Abstract 3526: Beta-oxidation inhibition as a novel therapy for cisplatin-resistant ovarian cancer

Abstract 1009: Reciprocal roles of cancer associated fibroblasts and CD4+ T cells in ovarian cancer progression

Abstract 5435: Role of the WT1 transcription factor in high-grade serous ovarian cancer

Abstract 3650: Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

Abstract 2975: Collagen type XI alpha 1 confers cisplatin chemoresistance in ovarian cancer through inhibitor of apoptosis proteins (IAPs)

Abstract A39: COL11A1 is a regulator of tumor microenvironment and a biomarker of metastatic progression

Abstract B09: Sphingosine kinase 1 (SPHK1) is a novel mediator of tumor-stroma interaction in ovarian cancer

Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance

Abstract 1534: Identification of LMX1B as a novel oncogene in human ovarian cancer

Abstract 1511: Stromal gene signature regulated by TGFβ signaling predicts poor clinical outcome in ovarian cancer .

Abstract 5443: FOXC1 is a critical mediator of EGFR function in basal-like breast cancer.

Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers.

Abstract 1749: Cell cycle requirements shape ovarian cancer progression.

Abstract 1088: HOXB13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines.

Abstract 1578: MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer

Abstract 5093: Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome

Abstract 3474: Ovarian cancer tumor initiating cells persist after paclitaxel and carboplatinum treatment in vivo

CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer

Abstract LB-387: Blockade of the CXCL12/CXCR4 axis with AMD3100 induces multimodal antitumor effects in murine ovarian cancer and prolongs survival

Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only